Levosimendan And Septic Cardiomyopathy: A Key That May Have Found Its Lock?

J Cardiothorac Vasc Anesth. 2023 Mar;37(3):350-352. doi: 10.1053/j.jvca.2022.12.012. Epub 2022 Dec 19.

Authors

Misty Radosevich¹, Etienne J Couture², Christoph Nabzdyk³

Affiliations

¹ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN. Electronic address: [email protected].
² Department of Anesthesiology and Department of Medicine, Division of Intensive Care Medicine, Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec, Canada.
³ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.

PMID: 36609077
DOI: 10.1053/j.jvca.2022.12.012

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cardiomyopathies* / diagnostic imaging
Cardiomyopathies* / drug therapy
Cardiotonic Agents / therapeutic use
Humans
Hydrazones / therapeutic use
Shock, Septic* / drug therapy
Simendan

Substances

Simendan
Cardiotonic Agents
Hydrazones